Over 60 ‘PET + tau’ clinical studies are currently active or recruiting to investigate tau load in many disease states including dementias, motor neuron diseases, traumatic brain injury, and depression, amongst others (clinicaltrails.gov, data obtained 30 October 2018). This evidence concerns the gene MAPT and depressive disorder.